152 related articles for article (PubMed ID: 19635727)
21. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
Ait Ouakrim D; Dashti SG; Chau R; Buchanan DD; Clendenning M; Rosty C; Winship IM; Young JP; Giles GG; Leggett B; Macrae FA; Ahnen DJ; Casey G; Gallinger S; Haile RW; Le Marchand L; Thibodeau SN; Lindor NM; Newcomb PA; Potter JD; Baron JA; Hopper JL; Jenkins MA; Win AK
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26109217
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
Mueller J; Gazzoli I; Bandipalliam P; Garber JE; Syngal S; Kolodner RD
Cancer Res; 2009 Sep; 69(17):7053-61. PubMed ID: 19690142
[TBL] [Abstract][Full Text] [Related]
23. Evidence for breast cancer as an integral part of Lynch syndrome.
Buerki N; Gautier L; Kovac M; Marra G; Buser M; Mueller H; Heinimann K
Genes Chromosomes Cancer; 2012 Jan; 51(1):83-91. PubMed ID: 22034109
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.
Ketabi Z; Bartuma K; Bernstein I; Malander S; Grönberg H; Björck E; Holck S; Nilbert M
Gynecol Oncol; 2011 Jun; 121(3):462-5. PubMed ID: 21388660
[TBL] [Abstract][Full Text] [Related]
25. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.
Niessen RC; Berends MJ; Wu Y; Sijmons RH; Hollema H; Ligtenberg MJ; de Walle HE; de Vries EG; Karrenbeld A; Buys CH; van der Zee AG; Hofstra RM; Kleibeuker JH
Gut; 2006 Dec; 55(12):1781-8. PubMed ID: 16636019
[TBL] [Abstract][Full Text] [Related]
26. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
27. Risk of pancreatic cancer in families with Lynch syndrome.
Kastrinos F; Mukherjee B; Tayob N; Wang F; Sparr J; Raymond VM; Bandipalliam P; Stoffel EM; Gruber SB; Syngal S
JAMA; 2009 Oct; 302(16):1790-5. PubMed ID: 19861671
[TBL] [Abstract][Full Text] [Related]
28. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
29. Analysis of mismatch repair gene mutations in Turkish HNPCC patients.
Tunca B; Pedroni M; Cecener G; Egeli U; Borsi E; Zorluoglu A; Di Gregorio C; Yilmazlar T; Yerci O; de Leon MP
Fam Cancer; 2010 Sep; 9(3):365-76. PubMed ID: 20373145
[TBL] [Abstract][Full Text] [Related]
30. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
[TBL] [Abstract][Full Text] [Related]
31. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
[TBL] [Abstract][Full Text] [Related]
32. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
33. MLH1 promoter germline-methylation in selected probands of Chinese hereditary non-polyposis colorectal cancer families.
Zhou HH; Yan SY; Zhou XY; Du X; Zhang TM; Cai X; Lu YM; Cai SJ; Shi DR
World J Gastroenterol; 2008 Dec; 14(48):7329-34. PubMed ID: 19109866
[TBL] [Abstract][Full Text] [Related]
34. The mutational spectrum of Lynch syndrome in cyprus.
Loizidou MA; Neophytou I; Papamichael D; Kountourakis P; Vassiliou V; Marcou Y; Kakouri E; Ioannidis G; Philippou C; Spanou E; Tanteles GA; Anastasiadou V; Hadjisavvas A; Kyriacou K
PLoS One; 2014; 9(8):e105501. PubMed ID: 25133505
[TBL] [Abstract][Full Text] [Related]
35. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
[TBL] [Abstract][Full Text] [Related]
36. Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
Baris HN; Barnes-Kedar I; Toledano H; Halpern M; Hershkovitz D; Lossos A; Lerer I; Peretz T; Kariv R; Cohen S; Half EE; Magal N; Drasinover V; Wimmer K; Goldberg Y; Bercovich D; Levi Z
Pediatr Blood Cancer; 2016 Mar; 63(3):418-27. PubMed ID: 26544533
[TBL] [Abstract][Full Text] [Related]
37. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.
Capelle LG; Van Grieken NC; Lingsma HF; Steyerberg EW; Klokman WJ; Bruno MJ; Vasen HF; Kuipers EJ
Gastroenterology; 2010 Feb; 138(2):487-92. PubMed ID: 19900449
[TBL] [Abstract][Full Text] [Related]
38. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
[TBL] [Abstract][Full Text] [Related]
39. Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome.
Bozzao C; Lastella P; Ponz de Leon M; Pedroni M; Di Gregorio C; D'Ovidio FD; Resta N; Prete F; Guanti G; Stella A
Cancer; 2011 Sep; 117(18):4325-35. PubMed ID: 21387278
[TBL] [Abstract][Full Text] [Related]
40. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]